



25 **Word count (text only):** 2991, 4 figures, 4 tables, 1 supplementary online content with 1 eMethod and 1

26 eFigure

27

28 **Corresponding author:**

29 Dr. Yves Longtin

30 Jewish General Hospital - SMBD

31 3755 Chemin de la Côte-Sainte-Catherine,

32 Montréal (Québec), Canada H3T 1E2

33 Tel: (514) 340.8294 ext 3731

34 Fax: (514) 340-7546

35 Email: [yves.longtin@mcgill.ca](mailto:yves.longtin@mcgill.ca)

36

37

38 **Funding:** Supported by the Ministère de la Santé et des Services Sociaux du Québec. The funding source

39 had no role in the design of the study, execution, analyses, interpretation of data, writing of report or

40 decision to submit the manuscript.

41

42 **Potential conflicts of interest:** Y. Longtin reports receiving research support from Summit (Oxford). All

43 other co-authors report no potential conflicts of interest.

44

45

46

47 **Abstract**

48 **Background:** There is a need to understand the duration of infectivity of primary and recurrent COVID-  
49 19 and identify predictors of loss of infectivity.

50 **Methods:** Prospective observational cohort study with serial viral culture, rapid antigen detection test  
51 (RADT) and RT-PCR on nasopharyngeal specimens of healthcare workers with COVID-19. The primary  
52 outcome was viral culture positivity as indicative of infectivity. Predictors of loss of infectivity were  
53 determined using multivariate regression model. The performance of the US CDC criteria (fever  
54 resolution, symptom improvement and negative RADT) to predict loss of infectivity was also  
55 investigated.

56  
57 **Results:** 121 participants (91 female [79.3%]; average age, 40 years) were enrolled. Most (n=107, 88.4%)  
58 had received  $\geq 3$  SARS-CoV-2 vaccine doses, and 20 (16.5%) had COVID-19 previously. Viral culture  
59 positivity decreased from 71.9% (87/121) on day 5 of infection to 18.2% (22/121) on day 10. Participants  
60 with recurrent COVID-19 had a lower likelihood of infectivity than those with primary COVID-19 at each  
61 follow-up (day 5 OR, 0.14;  $p < 0.001$ ; day 7 OR, 0.04;  $p = 0.003$ ) and were all non-infective by day 10  
62 ( $p = 0.02$ ). Independent predictors of infectivity included prior COVID-19 (adjusted OR [aOR] on day 5,  
63 0.005;  $p = 0.003$ ), a RT-PCR Ct value  $< 23$  (aOR on day 5, 22.75;  $p < 0.001$ ), but not symptom improvement  
64 or RADT result.

65 The CDC criteria would identify 36% (24/67) of all non-infectious individuals on Day 7. However, 17%  
66 (5/29) of those meeting all the criteria had a positive viral culture.

67 **Conclusions:** Infectivity of recurrent COVID-19 is shorter than primary infections. Loss of infectivity  
68 algorithms could be optimized.

69 Word count: 250

70

## 71 Introduction

72 Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2  
73 (SARS-CoV-2).<sup>1</sup> The current evidence regarding duration of infectivity rely on viral culture to detect  
74 shedding of replication-competent virus (also called viable or infectious virus). These studies suggest  
75 that immunocompetent individuals with non-severe COVID-19 can remain infective for up to 10 days.<sup>2-6</sup>

76

77 While infective, healthcare workers (HCWs) with COVID-19 must refrain from working to prevent  
78 nosocomial transmission.<sup>7,8</sup> However, the timing of their return to work is complicated by the  
79 interindividual variation in the durations of infectivity. Approximately a fifth of individuals may be  
80 infective for as little as 5 days, while approximately a quarter can remain infective for 10 days or more.<sup>9</sup>  
81 Determinants of loss of infectivity are largely unknown, but could be useful to optimize the return-to-  
82 work of infected HCWs. To limit absenteeism,<sup>10</sup> the US Centers for Disease Control and Prevention (CDC)  
83 and European CDC have provided guidance to allow earlier return to work of eligible HCWs.<sup>7,8</sup> These  
84 algorithms use readily available information such as symptom improvement and the result of rapid  
85 antigen detection tests (RADT) to predict loss of infectivity.<sup>7,8</sup> However, whether these criteria can  
86 reliably distinguish infective and non-infective individuals remain unclear.

87

88 Furthermore, many studies that investigated duration of infectivity were conducted early in the  
89 pandemic when individuals were infected for the first time, and often were unvaccinated. Few studies  
90 have investigated duration of infectivity of recurrent COVID-19.<sup>9</sup> Hence, we sought to evaluate the  
91 duration of infectivity of HCWs infected with primary and recurrent COVID-19, and identify predictors of  
92 infectivity using viral culture as a marker of infectivity.

93

94

95 **Methods**

96 *Study population*

97 We conducted a prospective observational cohort study at the CIUSSS Centre-Ouest-de-Montréal, a  
98 large healthcare organization employing 12,000 HCWs across 20 institutions. Participants were  
99 identified through the Occupational Health Service. Inclusion criteria included (1) SARS-CoV-2 infection  
100 confirmed by reverse transcription polymerase chain reaction (RT-PCR) from a nasopharyngeal  
101 specimen, and (2) symptom onset <72h prior to enrolment. Exclusion criteria included asymptomatic  
102 infections; moderate-to-severe COVID-19 (WHO Ordinal Scale for Clinical Improvement  $\geq 3$ )<sup>11</sup>;  
103 contraindication to nasopharyngeal sampling; and use of COVID-19-specific therapies (e.g. antivirals or  
104 monoclonal antibodies). Participants were followed on the 5<sup>th</sup>, 7<sup>th</sup> and 10<sup>th</sup> day of their infection (with  
105 the day of onset of symptoms defined as day 1).

106

107 The study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
108 guideline,<sup>12</sup> and was approved by local research ethics committees. Written informed consent was  
109 obtained from participants.

110

111 *Data collection*

112 Clinical data included sociodemographic information, medical history (including prior COVID-19  
113 infection), COVID-19 vaccination status (including number of doses and manufacturer), and  
114 symptomatology. We also assessed the use of antipyretics (acetaminophen and non-steroidal anti-  
115 inflammatory drugs) among afebrile participants as their use can mask fever. Participants reported this  
116 information online (LimeSurvey GmbH, Hamburg, Germany).

117

118 *Outcome definitions*

119 SARS-CoV-2 infectivity was defined as evidence of cytopathic effect (CPE) on microscopy of viral culture  
120 from a nasopharyngeal specimen, with etiology of the CPE being confirmed as SARS-CoV-2 by RT-PCR on  
121 the culture supernatant demonstrating at least 3 cycle threshold (Ct) values lower than the RT-PCR on  
122 the original sample.<sup>13</sup> Duration of infectivity was defined as the number of days between the onset of  
123 symptoms and the last positive culture.

124

#### 125 *Laboratory methods*

126 Nasopharyngeal samples using a flocked swab (FLOQSwabs, Copan Italia) were placed in 3ml universal  
127 viral transport media (UTM, Copan Italia) and kept at -80°C. Primary samples and culture supernatants  
128 were processed with an in-house RT-PCR targeting the SARS-CoV-2 N gene as previously described.<sup>14</sup>

129 Forward, reverse and probe sequences were as follows: AACCAGAATGGAGAACGCAGTG,

130 CGGTGAACCAAGACGCAGTATTAT and CGATCAAACAACGTCGGCCCCAAGGTTTAC .<sup>14</sup>

131

132 Viral cultures were performed on Vero E6 cells as previously described.<sup>14</sup> This cell line is commonly used  
133 to cultivate SARS-CoV-2 and has a median tissue culture infectious dose (TCID<sub>50</sub>) ranging between  
134 2.0E+04 to 6.3E+06.<sup>15</sup> A 0.1 ml aliquot of specimen was used as an inoculum. Cultures were kept for 15  
135 days.

136

137 All initial samples were sequenced to determine SARS-CoV-2 lineage using the Illumina technology. Data  
138 analysis was performed using the GenPipes Covseq pipeline<sup>16</sup> and variant identification was performed  
139 with Pangolin program (see appendix for details).<sup>17</sup>

140

141 Lateral-flow RADT were provided for self-administration (COVID-19 Antigen Rapid Test, BTNX, Hannover,  
142 Germany). Participants performed the test on a self-sampled midturbinate swab specimen by following

143 the manufacturer's instructions and interpreted the test result as positive, negative, or uncertain.<sup>18</sup>

144

145 *Sample size estimate*

146 Based on studies indicating that 25% of individuals remain infective on the 7<sup>th</sup> day of their infection,<sup>19</sup> we  
147 estimated that recruiting 120 participants would provide a precision of +/- 7% at the 95% confidence  
148 interval (CI).

149

150 *Statistical analyses*

151 Descriptive statistics reported discrete variables as numbers and proportions, and continuous variables  
152 as mean  $\pm$  standard deviation (SD) or median and interquartile ranges (IQR). The primary outcome was  
153 the proportion of HCWs with evidence of infectivity on the 5<sup>th</sup>, 7<sup>th</sup> and 10<sup>th</sup> day of their infection.

154

155 To investigate the capacity of the RT-PCR Ct value (an indicator of viral load that is inversely proportional  
156 to the quantity of nucleic acid in a sample) and RADT to predict infectivity, the Ct values of RT-PCR of  
157 samples with positive vs negative viral culture was depicted in the form of boxplots with overlaid jitter  
158 plot.

159

160 To investigate factors associated with persistent infectivity, odds ratios (OR) and 95% confidence  
161 intervals (CI) were estimated using bivariate and multivariate logistic regression at each follow-up visit.  
162 Multivariate models included clinical characteristics (symptom severity, symptom resolution, and fever)  
163 and results laboratory assays (RADT and RT-PCR) collected at each follow-up, as well as baseline  
164 individual (age, sex and immunological status) and viral (SARS-CoV-2 lineage) information. These  
165 variables were pre-defined as potential predictors of duration of infectivity according to literature and  
166 current practices.<sup>7,8</sup> Categories were grouped when necessary for model convergence. Variables



167 perfectly predicting the presence of infectivity could not be included in the corresponding multivariate  
168 model. Immunologic status was categorized according to vaccination and prior infection as follows:  
169 recent vaccination (last dose received <6 months ago) without prior infection; non-recent vaccination  
170 (last dose received  $\geq$ 6 months ago) without prior infection; and hybrid immunity (vaccination at any  
171 time and prior infection).

172

### 173 *Performance of return-to-work algorithms*

174 We estimated the capacity of the CDC algorithm to discriminate infective and non-infective HCWs on  
175 day 7 of their infection.<sup>7</sup> We also quantified the probability of an infectious HCW returning to work, and  
176 estimated the impact of these criteria to limit absenteeism. Finally, we explored the performance of  
177 alternative algorithms to predict loss of infectivity that were derived from variables identified in the  
178 current study. These evaluations assumed that in the absence of return-to-work criteria, HCWs would  
179 return to work 10 days after the onset of their symptoms.

180

181 All analyses were performed in SAS version 9.4. All tests were 2-tailed and a p-value < 0.05 was  
182 considered statistically significant. Adjustment for multiple comparisons were not applied in this  
183 exploratory study.<sup>20,21</sup>

184

### 185 *Role of Funding source*

186 The study was sponsored by the Ministère de la Santé et des Services Sociaux du Québec. The sponsor  
187 had no role in the design, conduct and reporting of the study.

188

189

## 190 **Results**

191 Between Feb 20<sup>th</sup> 2022 and March 6<sup>th</sup>, 2023<sup>th</sup>, 237 patients were offered to participate, and 121 (51.1%)  
192 were included in the analyses (**Figure 1**). Overall, 714 specimens (360 nasopharyngeal and 354 mid-  
193 turbinate swabs) were collected. Baseline characteristics of participants are shown in **Table 1**; 79.3%  
194 (96/121) were female, and the average age was 40.2 (SD, 12.0 years). The infections were due to  
195 multiple Omicron lineages including BA.1 (11.6%), BA.2 (60.3%), and BA.5 (8.3%), inclusive of  
196 sublineages. Virtually all participants (98.3%) were previously immunized with  $\geq 1$  dose of SARS-CoV-2  
197 vaccine. Most (84.3%) had received 3 doses, most commonly the Pfizer–BioNTech Comirnaty (89.3% of  
198 all received doses). The median elapsed time between the last dose and the current infection was 122  
199 days (IQR, 95-175 days). Twenty (20) participants (16.5%) had a prior COVID-19 episode. All these  
200 previous episodes were mild (WHO Grade scale  $\leq 2$ ) and occurred a median of 347.5 days prior to the  
201 current episode (IQR, 264 to 454 days).

202

### 203 *Symptoms of current COVID-19*

204 Upon enrollment, all participants described their infection as either “very mild” or “mild” (WHO Grade  
205 scale of 1 or 2). The most common symptoms were sore throat (77.7%), rhinorrhea and/or nasal  
206 congestion (72.7%) and fatigue (66.9%). The clinical evolution was favourable. No participant was  
207 hospitalized. A single participant received nirmatrelvir-ritonavir after enrollment. The proportion of  
208 participants with markedly improved or resolved symptoms increased from 43.8% on day 5 to 84.3% on  
209 day 10 (data not shown). Fever was uncommon: only 14.9% were febrile on enrollment. However,  
210 antipyretic use was frequent in afebrile individuals. For example, they were used by 50% and 31% of  
211 afebrile individuals on day 5 and 7 of their infection, respectively.

212

### 213 *Evolution of infectivity and viral shedding*

214 The proportion of participants with a positive viral culture was 71.9% (87/121; 95% CI, 63.0% to 79.7%)  
215 on day 5, 46.7% (56/120; 95% CI, 37.5% to 56.0%) on day 7 and 18.2% (22/121; 95% CI, 11.8% to 26.2%)  
216 on day 10, respectively (**Figure 1**). The proportion of participants with a positive RT-PCR decreased from  
217 93.3% (112/120) on day 5 (median Ct value, 23.4 (IQR, 20.6-27.9)) to 61.2% (74/120) on day 10 (median  
218 Ct value, 32.5 (IQR, 28.5 to undetectable)). Similarly, the proportion of RADT tests that were positive  
219 decreased progressively from 81.5% (97/119) on day 5, to 34.2% (40/117) on day 10.

220

### 221 *Factors associated with infectivity*

222 In bivariate analysis, multiple variables were associated with a positive viral culture (**Table 2**). A history  
223 of previous COVID-19 was strongly associated with a decreased likelihood of infectivity at each follow-up  
224 visit. Only 35% (7/20) of individuals with recurrent COVID-19 were still infective on day 5 compared with  
225 79% of those with a primary episode (OR, 0.14; 95% CI 0.05-0.40;  $p < 0.001$ ). Similarly, only 5% (1/20) of  
226 participants with recurrent COVID-19 were still infective on day 7, compared with 55% (55/100) of those  
227 with a first episode (OR, 0.04; 95% CI, 0.01-0.33;  $p = 0.003$ ). Finally, the proportion of participants with  
228 primary vs recurrent infection that were still infective on day 10 were 22% vs. 0%, respectively ( $p = 0.02$   
229 by Fisher's).

230

231 In terms of lineage, the BA.1 lineage was associated with a higher likelihood of infectivity on each  
232 follow-up visit than the BA.2 ( $p \leq 0.02$ ), while no difference was detected between BA.2 and BA.4/5.

233

234 In terms of clinical features, a lack of symptom improvement was predictive of ongoing infectivity on day  
235 7 (OR, 4.81;  $p = 0.01$ ) but not on day 5 or 10. Also, when compared to afebrile individuals who were not  
236 using antipyretics, those who were still using antipyretics were more likely to be infective at each follow  
237 up visit (range of OR, 2.97 to 4.26;  $p \leq 0.01$  for each comparison).

238

239 In terms of laboratory assays, a positive RADT result was associated with a higher likelihood of infectivity  
240 at day 5 (OR, 6.16;  $p=0.004$ ) and day 7 (OR, 10.93;  $p<0.001$ ). A positive RT-PCR was also significantly  
241 associated with infectivity at each follow-up, and there was an inverse association between the RT-PCR  
242 Ct value and ongoing infectivity (**Figure 2**). Notably, participants with recurrent COVID-19 differed from  
243 those with primary infection in terms of laboratory assays. At each visit, they had significantly higher RT-  
244 PCR Ct values (**Figure 3**) and were significantly more likely to have a negative RADT test result (**Table 3**).

245

246 In multivariate analysis (**Table 4**), the following variables were independently associated ongoing  
247 infectivity: A RT-PCR Ct value  $<23$  was independently associated with an increased probability of  
248 infectivity on each follow-up visit (adjusted OR [aOR] on day 5, 22.75;  $p<0.001$ ; aOR on day 7, 182.30;  
249  $p<0.001$ ; and aOR on day 10; 24.71;  $p=0.02$ ). A Ct value ranging between 23 and 27 was also predictive  
250 of ongoing infectivity at Day 7 and Day 10. A history of previous COVID-19 was independently associated  
251 with a decreased probability of infectivity on day 5 (aOR, 0.005;  $p<0.001$ ). By contrast, there was no  
252 significant association between ongoing infectivity and the absence of fever (with or without the use of  
253 antipyretics), symptom improvement, or RADT results.

254

#### 255 *Performance of return-to-work algorithms*

256 We applied the US CDC criteria to our cohort to identify non-infectious individuals on day 7 of COVID-19  
257 (**Figure 4**).<sup>7</sup> Approximately three quarters (88/117; 75.2%) would be ineligible for return to work because  
258 of fever ( $n=3$ ), the use of antipyretics ( $n=35$ ), a lack of symptom improvement ( $n=3$ ) or a positive RADT  
259 ( $n=47$ ). Hence, only 29 HCWs (24.8%) would meet all the return-to-work criteria. Of these, 17.2% (5/29)  
260 were infectious by viral culture, and 82.8% (24/29) were non-infectious. Hence, this algorithm could  
261 identify a third (35.8%; 24/67) of all non-infectious individuals on day 7. If all 29 HCWs who fulfilled all

262 criteria returned to work on day 7, this algorithm would decrease absenteeism by 7.4%.

263

264 We applied an alternative algorithm that used a history of previous COVID-19 and a RT-PCR Ct value >27

265 to predict loss of infectivity on day 7. This algorithm would identify 56.4% (66/117) of all HCWs as

266 eligible for return to work and could avoid 198 days of absence (16.9%). Of these, 52 (78.8%) were non-

267 infectious, and 14 (21.2%) were infectious. This algorithm would identify a greater proportion of all non-

268 infectious HCWs than the CDC algorithm (77.6% vs 35.8%;  $p < 0.001$ ). Even though it would return to

269 work a greater absolute number of infectious individuals, it would not significantly increase in the

270 probability of returning to work an infectious HCW (21.2% vs 17.2% of all eligible HCWs,  $p = 0.78$ ).

271

272 Given that approximately two thirds of individuals with recurrent COVID-19 were non-infectious by day

273 5, we explored various criteria that could accelerate their return-to-work (**eFigure 1** in supplementary

274 appendix). Among these, a RT-PCR Ct value >27 could identify most (77%; 10/13) non-infectious

275 individuals on day 5 with low probability (9%; 1/11) of returning to work an infectious HCW.

276

277

## 278 **Discussion**

279 Healthcare workers with COVID-19 must be removed from work, but their absence can exacerbate staff

280 shortages.<sup>22</sup> There is a need to identify predictors of loss of infectivity of SARS-CoV-2 to prevent

281 unwarranted prolongation of absence. Most published studies on this topic have relatively low number

282 of participants limiting the identification of predictors of loss of infectivity.<sup>6,23,24</sup>

283

284 In this prospective study, approximately three quarters (71.9%) were still shedding infectious viral

285 particles on 5<sup>th</sup> day of infection, half (46.7%) on the 7<sup>th</sup> day, and a fifth (18.2%) on the 10<sup>th</sup> day. These

286 results, along with other recent publications,<sup>25-28</sup> differ from those of earlier studies that estimated the  
287 duration of infectivity to 10 days or less.<sup>6,29</sup> A study of 66 individuals infected with the Omicron variant  
288 BA.1 reported that a quarter of participants were still infective on the 10<sup>th</sup> day of infection.<sup>9</sup> In another  
289 recent study, 8.5% were still shedding viable virus on day 14.<sup>30</sup>

290  
291 However, our study also identifies important nuances regarding durations of infectivity. Nowadays, an  
292 increasing proportion of infections occurs in individuals who have hybrid immunity due to vaccination  
293 and previous COVID-19. Our study identified that vaccinated individuals with recurrent COVID-19 have a  
294 significantly shorter duration of infectivity as well as a distinct viral kinetic as evidenced by lower viral  
295 loads and earlier negativisation of RADT. A prepublication study of 1400 professional athletes also  
296 reported faster viral clearance by RT-PCR in individuals with recurrent COVID-19 compared with primary  
297 infections (4.9 vs 7.2 days, respectively).<sup>31</sup> A cohort study in Alaska recently reported that individuals  
298 with previous COVID-19 infections were less likely to have a positive RADT result by day 5 compared to  
299 those with primary COVID-19.<sup>25</sup> A similar phenomenon has been described with other *Coronaviridae*. A  
300 study performed three decades ago among volunteers infected with coronavirus 229E determined that  
301 reinfections led to a shorter duration of virus shedding compared with the primary episode.<sup>32</sup> Taken  
302 together, these findings profoundly alter our understanding of the infectivity and viral kinetic of  
303 recurrent COVID-19.

304  
305 Our study also identified that a higher RT-PCR Ct value was the strongest independent predictor of loss  
306 of infectivity. This confirms findings from other studies that demonstrated that higher Ct values  
307 correspond with a non-replicative virus<sup>3,26,33-39</sup>. Hence, RT-PCR Ct values could help determine the timing  
308 of return to work of HCWs. A negative RADT result was also predictive of loss of infectivity by bivariate  
309 analysis.<sup>40</sup> However, our multivariate analysis indicates that RT-PCR Ct values hold superior predictive

310 capacity.

311

312 Our study also suggests that the guidance provided by the CDC to accelerate the return to work of  
313 infected HCWs is relatively stringent as it allows the return to work of only a third of all non-infectious  
314 individuals.<sup>7,8</sup> Also, they appear to have moderate discriminatory power as up to a sixth of those eligible  
315 for return to work are still shedding viable virus. By contrast, an alternative algorithm using RT-PCR Ct  
316 values and a history of previous COVID-19 could be able to return to work a greater proportion of HCWs  
317 on Day 7 without significantly increasing the probability of returning to work an infectious HCW.

318 Importantly, the performance of these algorithms will be influenced by whether the COVID-19 episode is  
319 a first episode or a recurrence. In our opinion, such distinction will be essential when updating these  
320 algorithms.

321

322 Our study has strengths. To our knowledge, this study is the first to demonstrate that individuals with  
323 recurrent COVID-19 have significantly shorter durations of infectivity using the gold standard of viral  
324 culture. It is among the largest that assessed infectivity using viral culture. Our laboratory technique was  
325 sensitive and could detect viable viruses in many individuals 10 days into their infection. It also has  
326 limitations. The study enrolled young, healthy, and highly immunized participants with mild COVID-19,  
327 so generalizability to other populations is uncertain. Even though culture positivity is the best marker of  
328 infectivity, the correlation between culture positivity and transmission remains unclear.<sup>9</sup> Additional  
329 studies, including validation with an external cohort, would be required to better inform return-to-work  
330 policies.<sup>20,21</sup>

331

332 In conclusion, our study detected a higher RT-PCR Ct value and COVID-19 reinfection as independent  
333 predictors of loss of infectivity in a highly vaccinated population, and suggests that return-to-work

334 algorithms could be optimized to limit absenteeism.<sup>10</sup> Further studies are needed to further characterize  
335 the viral kinetics of COVID-19 reinfections as they appear to fundamentally differ from those with  
336 primary COVID-19.

337

338

### 339 **Acknowledgements**

340

341 **Conflict of Interest Disclosures:** Dr Longtin reported receiving a grant from Summit (Oxford) outside the  
342 submitted work. No other disclosures were reported.

343

344 **Funding/Support:** This work was supported by the Ministère de la Santé et des Services Sociaux du  
345 Québec. The sponsor was not involved in the design and conduct of the study; collection, management,  
346 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and  
347 decision to submit the manuscript for publication.

348

349 **Data Access, Responsibility, and Analysis:** Yves Longtin had full access to all the data in the study and  
350 takes responsibility for the integrity of the data and the accuracy of the data analysis. Data not publicly  
351 available.

352

### 353 **Author Contribution:**

354 Concept and Design: Dzieciolowska, Fafard, Charest, De Serres, J. Longtin, Villeneuve, Y. Longtin

355 Acquisition, analysis, or interpretation of data: Dzieciolowska, Roy, Charest, Fafard, Levade, Beaulac,  
356 Parkes, Y. Longtin

357 Drafting of manuscript: Dzieciolowska, Y. Longtin



358 Critical revision of the manuscript for important intellectual content: Charest, Roy, Fafard, Carazo,  
359 Levade, J. Longtin, Parkes, Beaulac, Villeneuve, Savard, Corbeil, De Serres,  
360 Statistical analyses: Carazo, De Serres, Y. Longtin  
361 Obtained funding: Y. Longtin, De Serres  
362 Administrative, technical or material support: Dzieciolowska, Y. Longtin  
363 Supervision: Y. Longtin, De Serres  
364  
365  
366

367 **Legends to figures**

368

369 **FIGURE 1.** Flow diagram of participant selection into the study and proportion of infective participants at  
370 each follow-up visit.

371

372

373 **FIGURE 2.** Box plot with overlaid jitter plot comparing SARS-CoV-2 RT-PCR Cycle threshold, rapid antigen  
374 diagnostic test (RADT) result and viral culture positivity at day 5, 7 and 10 of COVID-19 among 121  
375 healthcare workers.

376 Footnote: The horizontal line in each box indicates the median, whereas the top and bottom of the  
377 boxes represent the 75th and 25th percentile, respectively. Error bars represent 95% confidence  
378 intervals. Negative RT-PCR results were attributed a Ct-value of 40 to facilitate data visualization.

379

380

381 **FIGURE 3.** Box plot comparing *SARS-CoV-2 RT-PCR Cycle threshold* at day 5, 7 and 10 of primary vs.  
382 recurrent COVID-19 infection.

383 Footnote: The horizontal line in each box indicates the median, whereas the top and bottom lines  
384 represent the 75th and 25th percentile, respectively. Error bars represent 95% confidence intervals.  
385 Negative RT-PCR results were attributed a Ct-value of 40 to facilitate data visualization. Comparison  
386 between primary vs recurrent infections assessed by Mann-Whitney U test.

387

388

389 **FIGURE 4.** Performance of return-to-work criteria for healthcare workers with COVID-19. **Panel A** shows  
390 the performance of the US Centers for Diseases Control and Prevention (US CDC) Return to Work criteria

391 on a cohort of healthcare workers with COVID-19. **Panel B** shows the performance of an alternative set  
392 of criteria derived from the current study. **Panel C** compares the CDC and alternative criteria.  
393

394       **REFERENCES**

- 395       1.   Helmy YA, Fawzy M, Elasad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19  
396            Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis,  
397            Treatment, and Control. *J Clin Med*. Apr 24 2020;9(4)doi:10.3390/jcm9041225
- 398       2.   Kadire SR, Fabre V, Wenzel RP. Doctor, How Long Should I Isolate? *N Engl J Med*. Mar 25  
399            2021;384(12):e47. doi:10.1056/NEJMcIde2100910
- 400       3.   Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and  
401            Transmission in a Skilled Nursing Facility. *N Engl J Med*. May 28 2020;382(22):2081-  
402            2090. doi:10.1056/NEJMoa2008457
- 403       4.   Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized  
404            patients with COVID-2019. *Nature*. May 2020;581(7809):465-469. doi:10.1038/s41586-  
405            020-2196-x
- 406       5.   Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic  
407            samples. *Clin Infect Dis*. May 22 2020;doi:10.1093/cid/ciaa638
- 408       6.   Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and  
409            MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a  
410            systematic review and meta-analysis. *Lancet Microbe*. Jan 2021;2(1):e13-e22.  
411            doi:10.1016/S2666-5247(20)30172-5
- 412       7.   US Centers for Diseases Control and Prevention. Interim Guidance for Managing  
413            Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 (2022).  
414            <https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html>.  
415            Accessed May 10, 2023.

- 416 8. European Centre for Disease Prevention and Control. Guidance on quarantine of close  
417 contacts to COVID-19 cases and isolation of COVID-19 cases, in the current  
418 epidemiological situation, 7 January 2022 (2022).  
419 [https://www.ecdc.europa.eu/en/covid-19/prevention-and-control/quarantine-and-](https://www.ecdc.europa.eu/en/covid-19/prevention-and-control/quarantine-and-isolation)  
420 [isolation](https://www.ecdc.europa.eu/en/covid-19/prevention-and-control/quarantine-and-isolation) Accessed May 10, 2023.
- 421 9. Boucau J, Marino C, Regan J, et al. Duration of Shedding of Culturable Virus in SARS-CoV-  
422 2 Omicron (BA.1) Infection. *N Engl J Med*. Jul 21 2022;387(3):275-277.  
423 doi:10.1056/NEJMc2202092
- 424 10. Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for health-  
425 care worker screening to prevent hospital transmission. *Lancet*. May 2  
426 2020;395(10234):1418-1420. doi:10.1016/S0140-6736(20)30917-X
- 427 11. World Health Organization. *WHO R&D Blueprint Novel Coronavirus COVID-19*  
428 *Therapeutic Trial Synopsis*. 2020. February 18, 2020.  
429 [https://cdn.who.int/media/docs/default-source/blue-print/covid-19-therapeutic-trial-](https://cdn.who.int/media/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf?sfvrsn=44b83344_1&download=true)  
430 [synopsis.pdf?sfvrsn=44b83344\\_1&download=true](https://cdn.who.int/media/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf?sfvrsn=44b83344_1&download=true)
- 431 12. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational  
432 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational  
433 studies. *J Clin Epidemiol*. Apr 2008;61(4):344-9. doi:10.1016/j.jclinepi.2007.11.008
- 434 13. Figueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2  
435 cell culture replication in respiratory samples from patients with severe COVID-19. *Clin*  
436 *Microbiol Infect*. Feb 22 2021;doi:10.1016/j.cmi.2021.02.014

- 437 14. Longtin Y, Charest H, Quach C, et al. Infectivity of healthcare workers diagnosed with  
438 coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A  
439 cross-sectional study. *Infect Control Hosp Epidemiol*. Jan 11 2021:1-3.  
440 doi:10.1017/ice.2020.1420
- 441 15. Wurtz N, Penant G, Jardot P, Duclos N, La Scola B. Culture of SARS-CoV-2 in a panel of  
442 laboratory cell lines, permissivity, and differences in growth profile. *Eur J Clin Microbiol*  
443 *Infect Dis*. Mar 2021;40(3):477-484. doi:10.1007/s10096-020-04106-0
- 444 16. CoV Sequencing Pipeline. [https://genpipes.readthedocs.io/en/genpipes-](https://genpipes.readthedocs.io/en/genpipes-v4.1.2/user_guide/pipelines/gp_covseq.html)  
445 [v4.1.2/user\\_guide/pipelines/gp\\_covseq.html](https://genpipes.readthedocs.io/en/genpipes-v4.1.2/user_guide/pipelines/gp_covseq.html), 2019.
- 446 17. O'Toole A, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an  
447 emerging pandemic using the pangolin tool. *Virus Evol*. 2021;7(2):veab064.  
448 doi:10.1093/ve/veab064
- 449 18. Papenburg J, Campbell JR, Caya C, et al. Adequacy of Serial Self-performed SARS-CoV-2  
450 Rapid Antigen Detection Testing for Longitudinal Mass Screening in the Workplace.  
451 *JAMA Netw Open*. May 2 2022;5(5):e2210559.  
452 doi:10.1001/jamanetworkopen.2022.10559
- 453 19. Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-  
454 CoV-2 human challenge in young adults. *Nat Med*. May 2022;28(5):1031-1041.  
455 doi:10.1038/s41591-022-01780-9
- 456 20. Bender R, Lange S. Adjusting for multiple testing--when and how? *J Clin Epidemiol*. Apr  
457 2001;54(4):343-9. doi:10.1016/s0895-4356(00)00314-0

- 458 21. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. Jan  
459 1990;1(1):43-6.
- 460 22. Poon YR, Lin YP, Griffiths P, Yong KK, Seah B, Liaw SY. A global overview of healthcare  
461 workers' turnover intention amid COVID-19 pandemic: a systematic review with future  
462 directions. *Hum Resour Health*. Sep 24 2022;20(1):70. doi:10.1186/s12960-022-00764-7
- 463 23. Keske S, Esken GG, Vatansever C, et al. Duration of infectious shedding of SARS-CoV-2  
464 omicron variant and its relation with symptoms. *Clin Microbiol Infect*. Jul 16  
465 2022;doi:10.1016/j.cmi.2022.07.009
- 466 24. Wu Y, Guo Z, Yuan J, et al. Duration of viable virus shedding and polymerase chain  
467 reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a  
468 systematic review and meta-analysis. *International journal of infectious diseases : IJID :  
469 official publication of the International Society for Infectious Diseases*. Feb 18  
470 2023;129:228-235. doi:10.1016/j.ijid.2023.02.011
- 471 25. Lefferts B, Blake I, Bruden D, et al. Antigen Test Positivity After COVID-19 Isolation —  
472 Yukon-Kuskokwim Delta Region, Alaska, January–February 2022. *MMWR Morbidity and  
473 Mortality Weekly Report*. 2022;71(8):293-298. doi:10.15585/mmwr.mm7108a3
- 474 26. Qi L, Yang Y, Jiang D, et al. Factors associated with the duration of viral shedding in  
475 adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect  
476 Dis*. Jul 2020;96:531-537. doi:10.1016/j.ijid.2020.05.045
- 477 27. Landon E, Bartlett AH, Marrs R, Guenette C, Weber SG, Mina MJ. High Rates of Rapid  
478 Antigen Test Positivity After 5 days of Isolation for COVID-19. Cold Spring Harbor  
479 Laboratory; 2022.

- 480 28. Stiefel U, Bhullar D, Zabarsky TF, et al. Healthcare personnel frequently have positive  
481 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen tests 5 days or  
482 more after diagnosis of coronavirus disease 2019 (COVID-19). *Infection Control &*  
483 *Hospital Epidemiology*. 2022:1-2. doi:10.1017/ice.2022.21
- 484 29. Takahashi K, Ishikane M, Ujiie M, et al. Duration of Infectious Virus Shedding by SARS-  
485 CoV-2 Omicron Variant-Infected Vaccinees. *Emerg Infect Dis*. May 2022;28(5):998-1001.  
486 doi:10.3201/eid2805.220197
- 487 30. Keske S, Guney-Esken G, Vatansever C, et al. Duration of infectious shedding of SARS-  
488 CoV-2 Omicron variant and its relation with symptoms. *Clin Microbiol Infect*. Feb  
489 2023;29(2):221-224. doi:10.1016/j.cmi.2022.07.009
- 490 31. Kissler SM, Hay JA, Fauver JR, et al. Viral kinetics of sequential SARS-CoV-2 infections.  
491 *medRxiv*. 2023:2023.03.03.23286775. doi:10.1101/2023.03.03.23286775
- 492 32. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to  
493 experimental coronavirus infection of man. *Epidemiol Infect*. Oct 1990;105(2):435-46.  
494 doi:10.1017/s0950268800048019
- 495 33. Gniazdowski V, Paul Morris C, Wohl S, et al. Repeated Coronavirus Disease 2019  
496 Molecular Testing: Correlation of Severe Acute Respiratory Syndrome Coronavirus 2  
497 Culture With Molecular Assays and Cycle Thresholds. *Clin Infect Dis*. Aug 16  
498 2021;73(4):e860-e869. doi:10.1093/cid/ciaa1616
- 499 34. Kim MC, Cui C, Shin KR, et al. Duration of Culturable SARS-CoV-2 in Hospitalized Patients  
500 with Covid-19. *N Engl J Med*. Feb 18 2021;384(7):671-673. doi:10.1056/NEJMc2027040



- 501 35. Longtin Y, Parkes LO, Charest H, et al. Persistence of infectivity in elderly individuals  
502 diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10  
503 days after onset of symptoms: A cross-sectional study. *Infect Control Hosp Epidemiol.*  
504 Dec 6 2021;1-4. doi:10.1017/ice.2021.502
- 505 36. Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory Syndrome  
506 Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis.* Dec 17 2020;71(10):2663-2666.  
507 doi:10.1093/cid/ciaa638
- 508 37. Aranha C, Patel V, Bhor V, Gogoi D. Cycle threshold values in RT-PCR to determine  
509 dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for  
510 COVID-19 patients. *J Med Virol.* Dec 2021;93(12):6794-6797. doi:10.1002/jmv.27206
- 511 38. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious  
512 potential assessment - a systematic review. *Clin Infect Dis.* Dec 3  
513 2020;doi:10.1093/cid/ciaa1764
- 514 39. Gniazdowski V, Morris CP, Wohl S, et al. Repeat COVID-19 Molecular Testing: Correlation  
515 of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds. *Clin Infect Dis.* Oct  
516 27 2020;doi:10.1093/cid/ciaa1616
- 517 40. Bouton TC, Atarere J, Turcinovic J, et al. Viral Dynamics of Omicron and Delta Severe  
518 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for  
519 Timing of Release from Isolation: A Longitudinal Cohort Study. *Clin Infect Dis.* Feb 8  
520 2023;76(3):e227-e233. doi:10.1093/cid/ciac510  
521  
522

523

524 **Table 1.** Demographic and clinical characteristics of healthcare workers with COVID-19

Characteristic	Overall population (n=121)
<b>Demographic characteristics</b>	
Mean Age – years (SD)	40.2 (12.0)
Female sex (%)	96 (79.3)
Workplace	
Acute care hospital (%)	56 (46.3)
Local Community Services Centers (%)	16 (13.2)
Long term care facilities (%)	15 (12.4)
Rehabilitation center (%)	9 (7.4)
Private clinic, family medicine clinic (%)	7 (5.8)
Other <sup>a</sup> (%)	18 (14.9)
<b>Occupation</b>	
Nurse, nurse practitioner, patient care attendant (%)	45 (37.2)
Physician (%)	20 (16.5)
Administration (%)	13 (10.7)
Physiotherapy, occupational therapy, social worker, radiology technician (%)	22 (18.2)
Other (%)	21 (17.4)
<b>Comorbidities and past medical history</b>	
Immunocompromised condition <sup>b</sup> (%)	4 (3.3)
<b>Previous COVID-19 episode (%)</b>	
Median elapsed time since last COVID-19 episode – days (IQR)	347.5 (264-454)
<b>COVID-19 Vaccination status</b>	
Not vaccinated (%)	2 (1.7)
1 dose (%)	3 (2.5)
2 doses (%)	9 (7.4)
3 doses (%)	102 (84.3)
4 doses (%)	5 (4.1)
<b>COVID-19 vaccine type (n=347 doses)<sup>d</sup></b>	
Pfizer-BioNTech Comirnaty (%)	310 (89.3)
Moderna Spikevax (%)	30 (8.6)

AstraZeneca Vaxzevria (%)	7 (2.0)	525
		526
		527
<b>Median elapsed time since last COVID-19 vaccine dose – days (IQR)</b>	122 (95-175)	528
		529
		530
<b>Severity of COVID-19 infection<sup>c</sup></b>		531
		532
Very mild (Ambulatory, no limitation of activities) (%)	97 (80.2)	533
		534
Mild (Ambulatory, with limitation of activities) (%)	24 (19.8)	535
		536
SARS-CoV-2 specific therapy <sup>e</sup> (%)	1 (0.8)	537
		538
		539
<b>COVID-19 symptomatology on enrollment</b>		540
		541
Median number of symptoms (IQR)	5 (3-6)	542
		543
Sore throat (%)	94 (77.7)	544
		545
Rhinorrhea and/or nasal congestion (%)	88 (72.7)	546
		547
Fatigue (%)	81 (66.9)	548
		549
Headache (%)	77 (63.6)	550
		551
Myalgia (%)	55 (45.5)	552
		553
Chills (%)	50 (41.3)	554
		555
Cough (%)	21 (17.4)	556
		557
Fever (%)	18 (14.9)	558
		559
Dizziness (%)	17 (14.0)	560
		561
Diarrhea (%)	14 (11.6)	562
		563
Nausea and/or vomiting (%)	10 (8.3)	564
		565
Chest pain (%)	10 (8.3)	566
		567
Dyspnea (%)	8 (6.6)	568
		569
Anosmia (%)	3 (2.5)	570
		571
Ageusia (%)	3 (2.5)	572
		573
		574
<b>SARS-CoV-2 lineage</b>		575
		576
BA.1 and sublineages (%)	14 (11.6)	577
		578
BA.2 and sublineages (%)	73 (60.3)	579
		580
BA.4 and sublineages (%)	3 (2.5)	581
		582
BA.5 (%)	10 (8.3)	583
		584
BQ.1 (%)	9 (7.4)	585
		586
XBB (%)	1 (0.8)	587
		588
Recombinants (%)	2 (1.7)	589
		590
Unknown (%)	9 (7.4)	591
		592

Footnotes  
a. Includes

593 vaccination center (n=3), research institute (n=5), rehabilitation centers (n=3), health phone services (n=5), cancer wellness center  
594 (n=1) and medical school (n=1)

- 595 b. Includes multiple sclerosis receiving fingolimod (n=1), multiple myeloma post autologous stem cell transplantation (n=1),
- 596 colorectal cancer under chemotherapy (n=1), and Crohn disease receiving anti-tumor necrosis factor (anti-TNF) therapy.
- 597 c. Severity determined by the World Health Organization Ordinal Scale for Clinical Improvement.
- 598 d. Sum of percentages is greater than 100% because of rounding
- 599 e. A single patient received nirmatrelvir and ritonavir after enrollment into the study

600  
601 Abbreviations: SD, standard deviation; IQR, interquartile range

602  
603  
604

**Table 2.** Predictors of infectivity on day 5, 7 and 10 of COVID-19 among healthcare workers (bivariate analyses)

Explanatory variable	Day 5					Day 7					Day 10				
	N <sup>b</sup>	Absence of infectivity	Presence of infectivity	OR (95% CI)	P-value <sup>c</sup>	N <sup>b</sup>	Absence of infectivity	Presence of infectivity	OR (95% CI)	P-value <sup>c</sup>	N <sup>b</sup>	Absence of infectivity	Presence of infectivity	OR (95% CI)	P-value <sup>c</sup>
		n (line %)	n (line %)				n (line %)	n (line %)				n (line %)	n (line %)		
<b>OVERALL</b>	121	34 (28.1)	87 (71.9)			120	64 (53.3)	56 (46.7)			121	99 (81.8)	22 (18.2)		
<b>Demographics</b>															
Median age (IQR)	121	40 (34-53)	38 (30-48)	NE	0.12	120	38.5 (31.5-49)	39.5 (32-48)	NE	0.99	121	38 (31-48)	39.5 (29-51)	NE	0.84
Male sex (%)	25	7 (28.0)	18 (72.0)	Ref		24	13 (20.3)	11 (19.6)	Ref		25	21 (84.0)	4 (16.0)	Ref	
Female sex (%)	96	27 (28.1)	69 (71.9)	0.99 (0.37-2.65)	0.99	96	51 (53.1)	45 (46.9)	1.04 (0.43-2.56)	0.93	96	78 (81.3)	18 (18.8)	1.21 (0.37-3.96)	0.75
<b>Previous infection status</b>															
No previous COVID-19	101	21 (20.8)	80 (79.2)	Ref		100	45 (45.0)	55 (55.0)	Ref		101	79 (78.2)	22 (21.8)	Ref	
Previous COVID-19	20	13 (65.0)	7 (35.0)	0.14 (0.05-0.40)	<0.001	20	19 (95.0)	1 (5.0)	0.04 (0.01-0.33)	0.003	20	20 (100)	0 (0.0)	NE	0.02
<b>Vaccination: number of doses received</b>															
No vaccination or one dose received	5	2 (40.0)	3 (60.0)	Ref		5	2 (40.0)	3 (60.0)	Ref		5	5 (100)	0 (0.0)	Ref	
≥2 doses received	116	32 (27.6)	84 (72.4)	1.75 (0.28-10.96)	0.55	115	62 (53.9)	53 (46.1)	0.57 (0.09-3.54)	0.55	116	94 (81.0)	22 (19.0)	NE	0.58
<b>Immunity status stratified by timing of last vaccine and previous COVID-19</b>															
No previous infection & last vaccine dose ≥6 months ago	12	2 (16.7)	10 (83.3)	Ref		11	7 (63.6)	4 (36.4)	Ref		12	11 (91.7)	1 (8.3)	Ref	
No previous infection & last vaccine dose <6 months ago	89	19 (21.3)	70 (78.7)	0.74 (0.15-3.65)	0.71	89	38 (42.7)	51 (57.3)	2.35 (0.64-8.60)	0.20	89	68 (76.4)	21 (23.6)	3.40 (0.41-27.87)	0.26
Previous infection, last vaccine dose > or < 6 months ago <sup>a</sup>	20	13 (65.0)	7 (35.0)	0.11 (0.02-0.64)	0.01	20	19 (95.0)	1 (5.0)	0.09 (0.01-0.97)	0.047	20	20 (100)	0 (0.0)	NE	0.38
<b>Rapid antigen detection test (RADT) result</b>															
Negative	13	8 (61.5)	5 (38.5)	Ref		34	29 (85.3)	5 (14.7)	Ref		64	64 (100)	0 (0)	Ref	
Positive	97	20 (20.6)	77 (79.4)	6.16 (1.82-20.88)	0.004	75	26 (34.7)	49 (65.3)	10.93 (3.78-31.60)	<0.001	40	22 (55.0)	18 (45.0)	NE	0.03
Uncertain	9	6 (66.7)	3 (33.3)	0.80 (0.13-4.75)	0.81	8	7 (87.5)	1 (12.5)	0.83 (0.08-8.27)	0.87	13	11 (84.6)	2 (15.4)	NE	<0.001
<b>SARS-CoV2 RT-PCR</b>															
Median Ct value (IQR)	120	28.5 (25.0-33.4)	21.8 (20.3-25.0)		<0.001	120	31.3 (27.4-35.6)	24.7 (22.9-27.4)		<0.001	120	35.5 (31.4-40.0)	26.7 (24.4-28.3)		0.002
Negative result	8	6 (75.0)	2 (25.0)	Ref		13	13 (100)	0 (0.0)	Ref		46	46 (100)	0 (0.0)	Ref	

Positive result	112	28 (25.0)	84 (75.0)	9.00 (1.72-47.17)	0.01	107	51 (47.7)	56 (52.3)	NE	<0.001	74	52 (70.3)	22 (29.7)	NE	<0.001
<b>RT-PCR cycle threshold (Ct) (reference: negative RT-PCR)</b>															
Ct value: 27 – 34	26	15 (57.7)	11 (42.3)	2.20 (0.37-13.04)	0.39	52	36 (69.2)	16 (30.8)	Ref (CT ≥27)		49	40 (81.6)	9 (18.4)	Ref (CT ≥27)	
Ct value: 23 - <27	27	9 (33.3)	18 (66.7)	6.00 (1.00-35.91)	0.05	39	13 (33.3)	26 (66.7)	6.12 (2.56-14.66)	<0.001	21	10 (47.6)	11 (52.4)	9.67 (1.21-77.12)	0.03
Ct value: 20 - <23	38	3 (7.9)	35 (92.1)	35.00 (4.79-255.47)	0.001	13	2 (15.4)	11 (84.6)	16.84 (3.37-84.17)	<0.001	4	2 (50.0)	2 (50.0)	10.63 (3.55-31.86)	<0.001
Ct value: <20	21	1 (4.8)	20 (95.2)	60.00 (4.60-782.36)	0.002	3	0 (0.0)	3 (100)	NE	0.02	0	0 (0.0)	0 (0.0)	NE	NE
<b>SARS-CoV-2 lineage</b>															
BA.2	73	21 (28.8)	52 (71.2)	Ref		73	39 (53.4)	34 (46.6)	Ref		73	62 (84.9)	11 (15.1)	Ref	
BA.1	14	0 (0.0)	14 (100.0)	NE	0.02	14	1 (7.1)	13 (92.9)	14.91 (1.85-199.99)	0.01	14	8 (57.1)	6 (42.9)	4.23 (1.23-14.57)	0.02
BA.4/5	13	3 (23.1)	10 (76.9)	1.35 (0.34-5.38)	0.67	12	8 (66.7)	4 (33.3)	0.57 (0.16-2.07)	0.40	13	10 (76.9)	3 (23.1)	1.69 (0.40-7.14)	0.48
Others (BQ.1, XBB.1, recombinant, unknown)	21	10 (47.6)	11 (52.4)	0.44 (0.16-1.20)	0.11	21	16 (76.2)	5 (23.8)	0.36 (0.12-1.08)	0.07	21	19 (90.5)	2 (9.5)	0.59 (0.12-2.91)	0.52
<b>Severity of symptoms</b>															
Asymptomatic	5	3 (60.0)	2 (40.0)	Ref		19	11 (57.9)	8 (42.1)	Ref		43	38 (88.4)	5 (11.6)	Ref	
Very mild (able to carry out regular activities of daily living)	105	28 (26.7)	77 (73.3)	4.12 (0.65-25.99)	0.13	92	50 (54.3)	42 (45.7)	1.16 (0.43-3.14)	0.78	73	58 (79.5)	15 (20.5)	1.97 (0.66-5.86)	0.23
Mild (Unable to carry out regular activities of daily living)	9	3 (33.3)	6 (66.7)	3.00 (0.31-28.84)	0.34	6	1 (16.7)	5 (83.3)	6.87 (0.67-70.81)	0.11	1	1 (100)	0 (0.0)	NE	1.000
<b>Evolution of symptoms</b>															
Symptoms are better or entirely gone	92	30 (32.6)	62 (67.4)	Ref		105	61 (58.1)	44 (41.9)	Ref		112	92 (82.1)	20 (17.9)	Ref	
Symptoms are the same or worse than before	27	4 (14.8)	23 (85.2)	2.78 (0.88-8.77)	0.08	12	1 (8.3)	11 (91.7)	4.81 (1.90-122.49)	0.01	5	5 (100)	0 (0.0)	NE	0.59
<b>Symptomatology</b>															
Fever and antipyretics use (last 24h)															
No fever, without antipyretics use	55	22 (40.0)	33 (60.0)	Ref		79	48 (60.8)	31 (39.2)	Ref		95	83 (87.4)	12 (12.6)	Ref	
No fever, with antipyretics use	55	9 (16.4)	46 (83.6)	3.41 (1.39-8.34)	0.007	35	12 (34.3)	23 (65.7)	2.97 (1.29-6.82)	0.01	21	13 (61.9)	8 (38.1)	4.26 (1.46-12.39)	0.008
Fever	9	3 (33.3)	6 (66.7)	1.33 (0.30-5.90)	0.71	3	2 (66.7)	1 (33.3)	0.77 (0.07-8.91)	0.84	1	1 (100)	0 (0.0)	NE	1.000
Presence of any symptom (last 48h)	91	22 (24.2)	69 (75.8)	2.35 (0.97-5.72)	0.06	78	38 (48.7)	40 (51.3)	1.68 (0.77-3.69)	0.19	66	52 (78.8)	14 (21.2)	2.02 (0.72-5.69)	0.18
Median Number of symptoms (IQR)	119	3 (42.9)	4 (57.1)	NA	0.14	117	2 (40)	3 (60)	NA	0.07	117	1 (33.3)	2 (66.7)	NA	0.41

Chills	15	1 (6.7)	14 (93.3)	6.51 (0.8251-5.9)	0.08	7	2 (28.6)	5 (71.4)	3.00 (0.56-16.13)	0.20	4	3 (75.0)	1 (25.0)	1.65 (0.16-16.72)	0.67
Cough	79	20 (25.3)	59 (74.7)	1.58 (0.70-3.62)	0.27	67	31 (46.3)	36 (53.7)	1.89 (0.90-4.00)	0.09	54	41 (75.9)	13 (24.1)	2.54 (0.93-6.92)	0.07
Fatigue	59	12 (20.3)	47 (79.7)	2.27 (1.00-5.16)	0.051	44	22 (50.0)	22 (50.0)	1.21 (0.57-2.56)	0.62	36	27 (75.0)	9 (25.0)	2.12 (0.79-5.69)	0.14
Myalgia	33	7 (21.2)	26 (78.8)	1.70 (0.66-4.40)	0.27	18	6 (33.3)	12 (66.7)	2.60 (0.90-7.50)	0.08	11	9 (81.8)	2 (18.2)	1.09 (0.22-5.46)	0.92
Sore throat	48	9 (18.8)	39 (81.3)	2.36 (0.98-5.64)	0.06	32	16 (50.0)	16 (50.0)	1.18 (0.52-2.66)	0.69	19	18 (94.7)	1 (5.3)	0.23 (0.03-1.84)	0.17
Headache	44	10 (22.7)	34 (77.3)	1.60 (0.68-3.77)	0.28	26	10 (38.5)	16 (61.5)	2.13 (0.87-5.21)	0.10	16	14 (87.5)	2 (12.5)	0.66 (0.14-3.16)	0.60
Dizziness	12	4 (33.3)	8 (66.7)	0.78 (0.22-2.78)	0.70	15	5 (33.3)	10 (66.7)	2.53 (0.81-7.94)	0.11	11	10 (90.9)	1 (9.1)	0.46 (0.06-3.79)	0.47
Rhinorrhea and/or congestion	82	19 (23.2)	63 (76.8)	2.26 (0.98-5.20)	0.055	65	31 (47.7)	34 (52.3)	1.16 (0.77-3.38)	0.20	47	36 (76.6)	11 (23.4)	2.07 (0.78-5.48)	0.14
Diarrhea	16	4 (25.0)	12 (75.0)	1.23 (0.37-4.13)	0.73	11	4 (36.4)	7 (63.6)	2.11 (0.58-7.66)	0.25	4	2 (50.0)	2 (50.0)	5.28 (0.70-39.93)	0.11
Loss of appetite	28	8 (28.6)	20 (71.4)	1.00 (0.39-2.55)	1.00	21	7 (33.3)	14 (66.7)	2.68 (0.99-7.24)	0.052	16	11 (68.8)	5 (31.3)	2.61 (0.79-8.57)	0.12

Footnote:

<sup>a</sup> Regardless of timing of last vaccine dose

<sup>b</sup> Among 121 participants with data on infectivity on day 5, 2 had missing information for RADT result and symptoms and 1 have missing information on RT-PCR CT result; among 120 participants with data on infectivity on day 7, 3 had missing information for RADT result and symptoms; among 121 participants with data on infectivity on day 10, 4 had missing information for RADT result and symptoms and 1 have missing information on RT-PCR CT result.

<sup>c</sup> Means were compared using student's t-test, proportions were compared using chi-square or fisher exact test when appropriate

Abbreviations: IQR, interquartile range; Ref, reference category; NE, No estimate could be calculated due to perfect correlation; NA, not applicable; RADT, Rapid antigen detection test; Ct, RT-PCR cycle threshold value

**Table 3. Comparison of rapid antigen detection test results of healthcare workers with primary vs recurrent COVID-19**

	Day 5 of infection			Day 7 of infection			Day 10 of infection		
	Primary COVID-19 N (%)	Recurrent COVID-19 N (%)	P-value	Primary COVID-19 N (%)	Recurrent COVID-19 N (%)	P-value	Primary COVID-19 N (%)	Recurrent COVID-19 N (%)	P-value
<b>RADT result (n)</b>	100	20		99	19		98	19	
Positive RADT	86 (86.0)	11 (57.9)	0.005	73 (73.7)	3 (15.8)	<0.001	40 (40.8)	0 (0.0)	<0.001
Negative RADT	7 (7.0)	6 (31.6)		18 (18.2)	16 (84.2)		45 (45.9)	19 (100)	
Uncertain RADT	7 (7.0)	2 (10.5)		8 (8.1)	0 (0.0)		13 (13.3)	0 (0.0)	

Abbreviation: RADT, Rapid antigen detection test



**Table 4.** Predictors of infectivity among HCWs with COVID-19 (multivariate analysis)

	Day 5 (n=121)			Day 7 (n=117)			Day 10 (n=117)		
	Adjusted OR	95% CI	P-value	Adjusted OR	95% CI	P-value	Adjusted OR	95% CI	P-value
<b>Female sex</b>	0.42	0.09-2.06	0.287	1.28	0.31-5.34	0.73	0.83	0.16-4.18	0.82
<b>Age (years)</b>									
20-39	Ref			Ref			Ref		
40-59	0.50	0.15-1.68	0.26	1.43	0.47-4.34	0.52	1.28	0.36-4.63	0.70
60-77	0.17	0.02-1.63	0.12	0.52	0.06-4.71	0.56	2.54	0.25-26.31	0.43
<b>Immunity status stratified by timing of last vaccine and previous COVID-19</b>									
No previous infection & last vaccine dose ≥6 months ago	Ref			Ref			Ref		
No previous infection & last vaccine dose <6 months ago	0.27	0.03-2.33	0.23	7.50	0.89-62.83	0.06	1.41	0.14-14.15	0.77
Previous infection, last vaccine dose > or < 6 months ago <sup>a</sup>	0.005	0.002-0.16	0.003	0.14	0.003-6.61	0.32	NE		
<b>RADT result</b>									
Negative	Ref			Ref			NE		
Positive	0.69	0.11-4.43	0.70	3.20	0.74-13.91	0.12	NE		
Uncertain	0.14	0.1-1.48	0.10	0.07	0.002-1.82	0.11	NE		
<b>SARS-CoV-2 RT-PCR Ct</b>									
≥27 (including negative)	Ref			Ref			Ref		
23 - <27	1.30	0.29-5.62	0.73	4.81	1.52-15.25	0.008	12.39	3.32-46.20	<0.001
14 - <23	22.75	3.89-133.05	<0.001	182.30	8.83-3764.36	0.001	24.71	1.53-398.50	0.02
<b>SARS-CoV-2 lineage<sup>b</sup></b>									

BA.1, BA.2 and subvariants	Ref			Ref			Ref		
BA.4, BA.5, BQ.1, XBB and subvariants	4.14	0.50-33.97	0.19	3.13	0.46-21.43	0.24	2.95	0.52-16.70	0.22
<b>Evolution of symptoms</b>									
Symptoms are better or entirely gone	Ref			Ref			NE		
Symptoms are the same or worse than before	0.52	0.11-2.57	0.42	18.67	0.98-355.49	0.05	NE		
<b>Fever and antipyretic use<sup>c</sup></b>									
No fever, without antipyretics use	Ref			Ref			Ref		
No fever, with antipyretics use	4.83	1.30-17.98	0.85	1.32	0.40-4.35	0.65	4.16	1.00-16.95	0.047
Fever	1.21	0.18-8.17	0.85	NA			NA		


**Footnote:**

<sup>a</sup> Regardless of timing of last vaccine dose


<sup>b</sup> For 9 individuals with missing information, lineage BA.1 / BA.2 or lineage BA.4 / BA.5 / BQ.1 / XBB were assigned based on circulating variants at the date of testing

<sup>c</sup> For the analyses of day 7 and day 10, “fever” and “no fever, with antipyretic use” were considered a single category

Abbreviations: CI, confidence interval; NE, not estimable; NA, not applicable; OR, odds ratio; RADT, Rapid antigen detection test; Ref, reference category; RT-PCR Ct, cycle threshold of real-time polymerase chain reaction




**FIGURE 1.** Flow diagram of participant selection into the study and proportion of infective participants at each follow-up visit.




**FIGURE 2.** Box plot with overlaid jitter plot comparing SARS-CoV-2 RT-PCR Cycle threshold, rapid antigen diagnostic test (RADT) result and viral culture positivity at day 5, 7 and 10 of COVID-19 infection among 121 healthcare workers.

Footnote: The horizontal line in each box indicates the median, whereas the top and bottom of the boxes represent the 75th and 25th percentile, respectively. Error bars represent 95% confidence intervals. Negative RT-PCR results were attributed a Ct-value of 40 to facilitate data visualization.



**FIGURE 3.** Box plot comparing *SARS-CoV-2 RT-PCR Cycle threshold* at day 5, 7 and 10 of primary vs. recurrent COVID-19 infection.

Footnote: The horizontal line in each box indicates the median, whereas the top and bottom lines represent the 75th and 25th percentile, respectively. Error bars represent 95% confidence intervals. Negative RT-PCR results were attributed a Ct-value of 40 to facilitate data visualization. Comparison between primary vs recurrent infections assessed by Mann-Whitney U test.



**FIGURE 4. Performance of return-to-work criteria for healthcare workers with COVID-19.** Panel A shows the performance of the US Centers for Diseases Control and Prevention (US CDC) Return to Work criteria on a cohort of healthcare workers with COVID-19. Panel B shows the performance of an alternative set of criteria derived from the current study. Panel C compares the CDC and alternative criteria.